(klin da mye' sin)


clindamycin hydrochloride


Cleocin, Cleocin Suppository, Dalacin C (CAN)


clindamycin palmitate hydrochloride


Cleocin Pediatric


clindamycin phosphate

Oral, parenteral, topical dermatologic solution for acne, vaginal preparation:

Cleocin Phosphate, Cleocin T, Cleocin Vaginal Ovules, Clinda-Derm (CAN), Clindagel, ClindaMax, Clindets, Dalacin C (CAN)


Pregnancy Category B


Drug class

Lincosamide antibiotic


Therapeutic actions

Inhibits protein synthesis in susceptible bacteria, causing cell death.



        Systemic administration: Serious infections caused by susceptible strains of anaerobes, streptococci, staphylococci, pneumococci; reserve use for penicillin-allergic patients or when penicillin is inappropriate; less toxic antibiotics (erythromycin) should be considered

        Parenteral: Treatment of septicemia caused by staphylococci, streptococci; acute hematogenous osteomyelitis; adjunct to surgical treatment of chronic bone and joint infections due to susceptible organisms; do not use to treat meningitis; does not cross the blood–brain barrier.

        Topical dermatologic solution: Treatment of acne vulgaris

        Vaginal preparation: Treatment of bacterial vaginosis


Contraindications and cautions

Systemic administration

        Contraindicated with allergy to clindamycin, history of asthma or other allergies, tartrazine (in 75- and 150-mg capsules); hepatic or renal dysfunction; lactation.

        Use cautiously in newborns and infants due to benzyl alcohol content; associated with gasping syndrome.

Topical dermatologic solution, vaginal preparation

        Contraindicated with allergy to clindamycin or lincomycin.

        Use cautiously with history of regional enteritis or ulcerative colitis; history of antibiotic-associated colitis.


Available forms

Capsules—75, 150, 300 mg; granules for oral solution—75 mg/5 mL; injection—150 mg/mL; topical gel—1%; topical lotion—1%; topical suspension—1%; vaginal cream—2%; vaginal suppository—100 mg





150–300 mg q 6 hr, up to 300–450 mg q 6 hr in more severe infections.


600–2,700 mg/day in two to four equal doses; up to 4.8 g/day IV or IM may be used for life-threatening situations.


One applicator (100 mg clindamycin phosphate) intravaginally, preferably at hs for 7 consecutive days; or insert vaginal suppository, preferably at hs for 7 consecutive days, 3 days for Cleocin Vaginal Ovules.


Apply a thin film to affected area bid.



For clindamycin HCl, 8–20 mg/kg/day in three or four equal doses. For clindamycin palmitate HCl, 8–25 mg/kg/day in three or four equal doses; for children weighing < 10 kg, use 37.5 mg tid as the minimum dose.


Neonates: 15–20 mg/kg/day in three or four equal doses.

> 1 mo: 15–40 mg/kg/day in three or four equal doses or 300 mg/m2/day to 400 mg/m2/day; in severe infections, give 300 mg/day regardless of weight.


Reduce dose, and monitor patient's serum levels carefully.









1–2 hr

8–12 hr


20–30 min

1–3 hr

8–12 hr




8–12 hr


Minimal systemic absorption




Metabolism: Hepatic; T1/2: 2–3 hr

Distribution: Crosses placenta; enters breast milk

Excretion: Urine and feces


IV facts

Preparation: Store unreconstituted product at room temperature. Reconstitute by adding 75 mL of water to 100-mL bottle of palmitate in two portions. Shake well; do not refrigerate reconstituted solution. Reconstituted solution is stable for 2 wk at room temperature. Dilute reconstituted solution to a concentration of 300 mg/50 mL or more of diluent using 0.9% sodium chloride injection, 5% dextrose injection, or lactated Ringer's solution. Solution is stable for 16 days at room temperature.

WARNING: Infusion: Do not administer more than 1,200 mg in a single 1-hr infusion. Infusion rates: 300 mg in 50 mL diluent, 10 min; 600 mg in 50 mL diluent, 20 min; 900 mg in 50–100 mL diluent, 30 min; 1,200 mg in 100 mL diluent, 40 min. Rapid infusion can cause cardiac arrest.

Incompatibilities: Do not mix with calcium gluconate, ampicillin, phenytoin, barbiturates, aminophylline, and magnesium sulfate. May be mixed with sodium chloride, dextrose, calcium, potassium, vitamin B complex, kanamycin, gentamicin, penicillin, carbencillin. Incompatible in syringe with tobramycin.


Adverse effects

Systemic administration

        CV: Hypotension, cardiac arrest (with rapid IV infusion)

        GI: Severe colitis, including pseudomembranous colitis, nausea, vomiting, diarrhea, abdominal pain, esophagitis, anorexia, jaundice, liver function changes

        Hematologic: Neutropenia, leukopenia, agranulocytosis, eosinophilia

        Hypersensitivity: Rashes, urticaria to anaphylactoid reactions

        Local: Pain following injection, induration and sterile abscess after IM injection, thrombophlebitis after IV use

Topical dermatologic solution

        CNS: Fatigue, headache

        Dermatologic: Contact dermatitis, dryness, gram-negative folliculitis

        GI: Pseudomembranous colitis, diarrhea, bloody diarrhea; abdominal pain, sore throat

        GU: Urinary frequency

Vaginal preparation

        GU: Cervicitis, vaginitis, vulvar irritation



Systemic administration

        Increased neuromuscular blockade with neuromuscular blocking agents

        Decreased GI absorption with kaolin, aluminum salts


Nursing considerations


        History: Allergy to clindamycin, history of asthma or other allergies, allergy to tartrazine (in 75- and 150-mg capsules); hepatic or renal dysfunction; lactation; history of regional enteritis or ulcerative colitis; history of antibiotic associated colitis

        Physical: Site of infection or acne; skin color, lesions; BP; R, adventitious sounds; bowel sounds, output, liver evaluation; complete blood count, renal and liver function tests



Systemic administration

        Culture infection before therapy.

        Administer oral drug with a full glass of water or with food to prevent esophageal irritation.

        Do not give IM injections of more than 600 mg; inject deep into large muscle to avoid serious problems.

        Do not use for minor bacterial or viral infections.

        Monitor renal and liver function tests, and blood counts with prolonged therapy.

Topical dermatologic administration

        Keep solution away from eyes, mouth and abraded skin or mucous membranes; alcohol base will cause stinging. Shake well before use.

        Keep cool tap water available to bathe eye, mucous membranes, abraded skin inadvertently contacted by drug solution.

Vaginal preparation

        Give intravaginally, preferably at hs.


Teaching points

Systemic administration

        Take oral drug with a full glass of water or with food.

        Take full prescribed course of oral drug. Do not stop taking without notifying health care provider.

        You may experience these side effects: Nausea, vomiting (eat frequent small meals); superinfections in the mouth, vagina (use frequent hygiene measures; request treatment if severe).

        Report severe or watery diarrhea, abdominal pain, inflamed mouth or vagina, skin rash or lesions.

Topical dermatologic administration

        Apply thin film of acne solution to affected area twice daily, being careful to avoid eyes, mucous membranes, abraded skin; if solution contacts one of these areas, flush with copious amounts of cool water.

        Report abdominal pain, diarrhea.

Vaginal preparation

        Use vaginal preparation for 7 or 3 consecutive days, preferably at bedtime. Refrain from sexual intercourse during treatment with this product.

        Report vaginal irritation, itching; diarrhea, no improvement in complaint being treated.


Adverse effects in Italic are most common; those in Bold are life-threatening.